These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 37400870)

  • 21. Nanostructured Antagonist of Extrasynaptic NMDA Receptors.
    Savchenko A; Braun GB; Molokanova E
    Nano Lett; 2016 Sep; 16(9):5495-502. PubMed ID: 27490923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
    Molinuevo JL; Lladó A; Rami L
    Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.
    Glasgow NG; Povysheva NV; Azofeifa AM; Johnson JW
    J Neurosci; 2017 Oct; 37(40):9686-9704. PubMed ID: 28877967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of N-acetyl-aspartyl-glutamate on synaptic and extrasynaptic NMDA receptors are subunit- and pH-dependent in the CA1 region of the mouse hippocampus.
    Khacho P; Wang B; Ahlskog N; Hristova E; Bergeron R
    Neurobiol Dis; 2015 Oct; 82():580-592. PubMed ID: 26303888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.
    Koch HJ; Szecsey A; Haen E
    Curr Pharm Des; 2004; 10(3):253-9. PubMed ID: 14754385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA; Wenk GL
    CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Effects of Pharmacologic and Genetic Modulation of NMDA Receptor Activity on HIV/gp120-Induced Neuronal Damage in an In Vivo Mouse Model.
    Nakanishi N; Kang YJ; Tu S; McKercher SR; Masliah E; Lipton SA
    J Mol Neurosci; 2016 Jan; 58(1):59-65. PubMed ID: 26374431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational investigation of Amyloid-β-induced location- and subunit-specific disturbances of NMDAR at hippocampal dendritic spine in Alzheimer's disease.
    Liang J; Kulasiri D; Samarasinghe S
    PLoS One; 2017; 12(8):e0182743. PubMed ID: 28837653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palmitoylation Controls NMDA Receptor Function and Steroid Sensitivity.
    Hubalkova P; Ladislav M; Vyklicky V; Smejkalova T; Hrcka Krausova B; Kysilov B; Krusek J; Naimová Z; Korinek M; Chodounska H; Kudova E; Cerny J; Vyklicky L
    J Neurosci; 2021 Mar; 41(10):2119-2134. PubMed ID: 33526476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures.
    Ferreira IL; Bajouco LM; Mota SI; Auberson YP; Oliveira CR; Rego AC
    Cell Calcium; 2012 Feb; 51(2):95-106. PubMed ID: 22177709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.
    Zádori D; Veres G; Szalárdy L; Klivényi P; Toldi J; Vécsei L
    J Alzheimers Dis; 2014; 42 Suppl 3():S177-87. PubMed ID: 24670398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Computer Simulation of Therapy with the NMDA Antagonist in Excitotoxic Neurodegeneration in an Alzheimer's Disease-like Pathology.
    Świetlik D; Kusiak A; Krasny M; Białowąs J
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strain hypothesis and additional evidence of the GluN3A deficiency-mediated pathogenesis of Alzheimer's disease.
    Yu SP; Jiang M; Berglund K; Wei L
    Alzheimers Dement; 2023 Sep; 19(9):4267-4269. PubMed ID: 37485581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Memantine in the treatment of mild-to-moderate Alzheimer's disease.
    Cosman KM; Boyle LL; Porsteinsson AP
    Expert Opin Pharmacother; 2007 Feb; 8(2):203-14. PubMed ID: 17257090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftriaxone improves impairments in synaptic plasticity and cognitive behavior in APP/PS1 mouse model of Alzheimer's disease by inhibiting extrasynaptic NMDAR-STEP
    He RB; Li L; Liu LZ; Ma YJ; Fan SJ; Liu LR; Li WB; Xian XH
    J Neurochem; 2023 Jul; 166(2):215-232. PubMed ID: 37284938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors.
    Léveillé F; El Gaamouch F; Gouix E; Lecocq M; Lobner D; Nicole O; Buisson A
    FASEB J; 2008 Dec; 22(12):4258-71. PubMed ID: 18711223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel method using ambient glutamate for the electrophysiological quantification of extrasynaptic NMDA receptor function in acute brain slices.
    Moldavski A; Behr J; Bading H; Bengtson CP
    J Physiol; 2020 Feb; 598(4):633-650. PubMed ID: 31876958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.